Overview
Clinical Meaning
Direct oral anticoagulants (DOACs) include factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) and the direct thrombin (factor IIa) inhibitor dabigatran.
AGPCNP
AGPCNP
Direct oral anticoagulants (DOACs) include factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) and the direct thrombin (factor IIa) inhibitor dabigatran. Unlike warfarin, DOACs have predictable pharmacokinetics that typically do not require routine laboratory monitoring. However, when life-threatening bleeding or emergent surgery occurs, rapid reversal is critical. Dabigatran reversal: Idarucizumab (Praxbind) is a humanized monoclonal antibody fragment (Fab) that binds dabigatran with ~350 times greater affinity than thrombin, effectively neutralizing ALL circulating dabigatran within minutes. Dose: 5 grams IV (two 2.5g vials) administered as two consecutive infusions. The RE-VERSE AD trial demonstrated complete reversal in 88% of patients within 4 hours. Idarucizumab is SPECIFIC to dabigatran — it does NOT reverse factor Xa inhibitors. Factor Xa inhibitor reversal: Andexanet alfa (Andexxa) is a modified recombinant factor Xa decoy protein that binds and sequesters factor Xa inhibitors (rivaroxaban, apixaban, and LMWH). It has no intrinsic procoagulant activity because the active site serine has been replaced with alanine. Dosing depends on the specific Xa inhibitor and time since last dose (low-dose vs. high-dose regimen). The ANNEXA-4 trial showed hemostatic efficacy in ~82% of patients....
Unlock full lesson + practice questions
4 more sections with scenarios, priorities, and review drills.
Final rapid review before practice
Next study step
Finish the lesson first, then choose a focused activity to apply what you just reviewed.
Continue studying
Sign in to save progress on this lesson.
Unlock the interactive lesson quiz with a plan that includes this AGPCNP pathway. You can still explore topic-filtered questions from the bank hubs below.